Analyst Scoreboard: 12 Ratings For Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
Nurix Therapeutics (NASDAQ:NRIX) has been analyzed by 12 analysts over the past three months, showing a range of bullish to somewhat bullish ratings. Analysts have set a 12-month average price target of $29.0, with a high of $35.00 and a low of $20.00. Recent ratings adjustments include several upgrades and a few maintained ratings. Despite a significant revenue decline, the company maintains a strong market position with a low debt-to-equity ratio.
July 15, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics has received mixed analyst ratings, with a 12-month average price target of $29.0. Recent ratings include several upgrades and a few maintained ratings. Despite a significant revenue decline, the company maintains a strong market position with a low debt-to-equity ratio.
The mixed but predominantly positive analyst ratings and the increase in the average price target suggest a short-term positive impact on NRIX's stock price. The company's strong market position and prudent debt management further support this outlook, despite the recent revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100